Skip to main content

Staphylococcal Skin Infection

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Cumberland Pharmaceuticals
2 programs
2
TelavancinPhase 31 trial
TelavancinPhase 31 trial
Active Trials
NCT00091819Completed862Est. Jun 2006
NCT00107978Completed1,035Est. May 2006
Theravance Biopharma
1 program
1
TD-1792Phase 21 trial
Active Trials
NCT00442832Completed203Est. May 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Cumberland PharmaceuticalsTelavancin
Cumberland PharmaceuticalsTelavancin
Theravance BiopharmaTD-1792

Clinical Trials (3)

Total enrollment: 2,100 patients across 3 trials

NCT00107978Cumberland PharmaceuticalsTelavancin

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Start: Feb 2005Est. completion: May 20061,035 patients
Phase 3Completed
NCT00091819Cumberland PharmaceuticalsTelavancin

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Start: Jan 2005Est. completion: Jun 2006862 patients
Phase 3Completed
NCT00442832Theravance BiopharmaTD-1792

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Start: Dec 2006Est. completion: May 2007203 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.